...
机译:英夫利昔单抗BioSimilar CT-P13类风湿性关节炎,炎症性肠疾病和强直性脊柱炎的观测研究:汇总分析长期安全性和有效性
Yonsei Univ Dept Internal Med Coll Med Seoul South Korea;
Soonchunhyuang Univ Hosp Dept Internal Med Cheonan South Korea;
Dongguk Univ Ilsan Hosp Coll Med Dept Internal Med Goyang South Korea;
Dongguk Univ Ilsan Hosp Coll Med Dept Internal Med Goyang South Korea;
Kyung Hee Univ Coll Med Dept Rheumatol Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Kyung Hee Univ Hosp Gangdong Arthrit &
Rheumatism Ctr Seoul South Korea;
Celltrion Inc Incheon South Korea;
Ankylosing spondylitis; Crohn's disease; CT-P13; Effectiveness; Infliximab biosimilar; Long-term; Post-marketing observational study; Rheumatoid arthritis; Safety; Ulcerative colitis;
机译:5年来回顾性分析类风湿性关节炎和强直性脊柱炎患者英夫利昔单抗生物仿生CT-P13的药物存活,安全性和有效性
机译:在治疗活性类风湿性关节炎或强直性脊柱炎的患者的真实寿命设定中,对生物仿制性英夫利昔单抗(CT-P13)的有效性和安全性评估
机译:在治疗活性类风湿性关节炎或强直性脊柱炎的患者的真实寿命设定中,对生物仿制性英夫利昔单抗(CT-P13)的有效性和安全性评估
机译:在EU5中采用生物仿制药英夫利昔单抗治疗类风湿性关节炎强直性脊柱炎和炎症性肠病:使用Delphi小组进行的预算影响分析
机译:POS0592 BioSimilar Infliximab疗法在类风湿性关节炎,强直性脊柱炎和银屑病关节炎:对富生素-Naïve患者的长期随访研究和从发起者转换为生物邮件CT-P13的患者
机译:Omega-3脂肪酸对II型糖尿病和代谢综合征以及炎症性肠病,类风湿性关节炎,肾病,系统性红斑狼疮和骨质疏松症的血脂和血糖控制的影响证据报告/技术